Figure 1.

GW501516 is a selective PPARδ agonist. Data are expressed as fold change compared with vehicle-treated cells and represent the mean of assays performed in triplicate ± SE. (A) Chemical structure of GW501516. (B) Activation of GAL4-PPAR ligand binding domain chimeras in transiently transfected CV-1 cells by GW501516. Dose–response curves are shown for human PPARδ (●), human PPARα (▵), and human PPARγ (□). (C) Activation of GAL4-nuclear receptor ligand binding domain chimeras in CV-1 cells. Transfected cells were treated with 1.0 μM GW501516.